A Novel Fibrinolysis Resistance Capacity Assay can Detect Fibrinolytic Phenotypes in Trauma Patients.
Christopher D Barrett, Yuko Suzuki, Ernest E Moore, Hunter B Moore, Elizabeth R Maginot, Collin M White, Halima Siddiqui, Flobater I Gawargi, James G Chandler, Angela Sauaia and 1 more
Article in Thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Christopher D BarrettDivision of Acute Care Surgery, Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, United States.ORCID 0000-0001-9720-8155
Yuko SuzukiDepartment of Medical Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan.ORCID 0000-0003-4833-8580
Ernest E MooreDepartment of Surgery, Ernest E Moore Shock Trauma Center at Denver Health, Denver, Colorado, United States.
Hunter B MooreDivision of Solid Organ Transplantation, Department of Surgery, AdventHealth Porter, Denver, Colorado, United States.ORCID 0000-0002-5939-3828
Elizabeth R MaginotDivision of Acute Care Surgery, Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, United States.
Collin M WhiteDepartment of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, United States.
Halima SiddiquiDivision of Acute Care Surgery, Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, United States.
Flobater I GawargiDepartment of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, United States.
James G ChandlerDepartment of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States.
Angela SauaiaSauaia Statistical Solutions, LLC, Denver, Colorado, United States.
Tetsumei UranoDepartment of Medical Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan.ORCID 0000-0002-7398-9732
Funding
Using Patient-Reported Outcomes, Inflammatory Profiles, and Cardiovascular Phenogroups to Expand the Definition of Heart Failure with Preserved Ejection FractionP20GM152326 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Marian Urban · 2024 to 2026
$10.3M
Mechanisms of Trauma-Induced CoagulopathyT32GM008315 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI Mitchell Cohen, ELIZABETH J. KOVACS · 1991 to 2026
$7.1M
Mechanisms of Complement Activation in Traumatic InjuryK08HL171936 · NHLBI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Christopher David Barrett · 2024 to 2026
$500k
Japan Agency for Medical Research and Development 21ek0210154h0002JSPS KAKENHI 22H03172JSPS KAKENHI 22K08153National Heart Lung and Blood Institute K08-HL171936NHLBI NIH HHS K08 HL171936NIGMS NIH HHS P20 GM152326NIGMS NIH HHS P20-GM152326NIGMS NIH HHS T32 GM008315NIGMS NIH HHS T32-GM008315
6 · The paper itself
Abstract
To evaluate residual fibrinolysis resistance activity (FRA) in plasma, a detergent-modified plasma clot lysis assay time (dPCLT) was established in which α2-antiplasmin (A2AP) and plasminogen activator inhibitor type 1 (PAI-1) are inactivated without impacting protease activity. We applied this novel assay to severely injured trauma patients' plasma.Tissue-type plasminogen activator (tPA)-induced plasma clot lysis assays were conducted after detergents- (dPCLT) or vehicle- (sPCLT) treatment, and time to 50% clot lysis was measured ("transition midpoint", T
Indexed as
Fibrin Clot Lysis TimeFibrinolysisMultiple TraumaWounds and InjuriesAdultAgedalpha-2-AntiplasminBiomarkersFemaleHumansMaleMiddle AgedPhenotypePlasminogen Activator Inhibitor 1Predictive Value of TestsThrombelastographyalpha-2-AntiplasminBiomarkersPlasminogen Activator Inhibitor 1SERPINE1 protein, humanTissue Plasminogen Activator
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Novel Fibrinolysis Resistance Capacity Assay can Detect Fibrinolytic Phenotypes in Trauma Patients. · full record | OpenQuestion